Our Pipeline

scPharmaceuticals’ pipeline includes product timelines for preclinical, through regulatory approval. We develop innovative pharmaceutical products on the basis of proven generics by creating the first anytime anywhere administration. Our proprietary sc2Wear™ Infusor technology enables convenient and comfortable subcutaneous administration– by patient or caregiver. Our solutions reduce the burden of disease for patients, providers and payors.

Heart Failure

Furosemide for Subcutaneous Delivery

Furosemide is a loop diuretic used in the treatment of congestive heart failure and edema. Approved in 1968, it is on the World Health Organization’s List of Essential Medicines. Approximately half of total direct healthcare spending for heart failure is to remove fluid from patients with hypervolemia. The average hospitalized patients loses 8.4L of water (approximately 18lbs) in over a little over 5 days. The cost per liter removal in a clinical setting ranges from $600 to $2,000. Subcutaneous administration enables diuresis at approximately 1/10th of the cost. Earlier convenient access should prevent hospitalizations and rehospitalizations. It can also be used to reduce length of stay from the current 5.8 days to between 3 and 4.0 days. Furosemide for Subcutaneous Delivery is a novel formulation with a neutral pH that is optimized for subcutaneous delivery. More

Preclinical Preclinical
Clinical Pivotal Market Development
Regulatory Regulatory Review
Q2
2015
Q3
2015
Q4
2015
Q1
2016
Q2
2016
Q3
2016
Q4
2016
Q1
2017
Q2
2017

Infectious Disease

Ceftriaxone for Subcutaneous Delivery

Ceftriaxone is the most widely-used drug in outpatient parenteral antibiotic therapy (OPAT) and is on the World Health Organization’s List of Essential Medicines. Approved in 1984, Ceftriaxone is used to treat a number of bacterial infections including lower respiratory tract infections, acute bacterial otitis media, skin and skin structure disease, bone and joint infections, lyme disease, urinary tract infection, bacterial septicemias, bacterial meningitis and other infections. Going from PICC-based to subcutaneous treatment avoids the PICC and associated risks and discomforts while reducing the financial and personal burden associated with current parenteral antibiotic therapy. More

Preclinical Preclinical
Clinical Pivotal Market Dev
Regulatory Regulatory Review
Q3
2015
Q4
2015
Q1
2016
Q2
2016
Q3
2016
Q4
2016
Q1
2017
Q2
2017

Ertapenem for Subcutaneous Delivery

Ertapenem, approved in 2001, is a broadly active antibacterial used for infections caused by difficult to treat or multidrug-resistant bacteria (gram negative and gram-positive). It is used in the treatment of complicated intra-abdominal infections, complicated skin and skin structure infections, diabetic foot infections, community acquired pneumonia, complicated urinary tract infections. The advantage of Ertapenem for Subcutaneous Delivery is that it enables avoidance of PICC lines and associated risks.

Preclinical Preclinical
Clinical Pivotal Market Development
Regulatory Regulatory Review
Q3
2017
Q4
2017
Q1
2018
Q2
2018
Q3
2018
Q4
2018
Q1
2019
Q2
2019